Drugs for non-HIV viral infections.
D015075:2-Aminopurine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000212:Acyclovir / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000284:Administration, Oral; D000287:Administration, Topical; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077595:Famciclovir; D017245:Foscarnet / Q000009:adverse effects; D006147:Guanine; D006566:Herpesviridae Infections / Q000188:drug therapy*; D006801:Humans; D007251:Influenza, Human / Q000517:prevention & control; D007275:Injections, Intravenous; D019259:Lamivudine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects; D051381:Rats; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012299:Rimantadine / Q000008:administration & dosage / Q000627:therapeutic use; D013873:Thionucleotides / Q000009:adverse effects / Q000627:therapeutic use; D014271:Trifluridine / Q000627:therapeutic use; D000077483:Valacyclovir; D014633:Valine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D013873:Thionucleotides; D012299:Rimantadine; D019259:Lamivudine; C053539:penciclovir; D017245:Foscarnet; D015075:2-Aminopurine; D012254:Ribavirin; D006147:Guanine; D003596:Cytosine; D000547:Amantadine; D014633:Valine; D000077404:Cidofovir; D000077483:Valacyclovir; D000077595:Famciclovir; C091346:fomivirsen; D014271:Trifluridine; D000212:Acyclovir